Program Description
This symposium was originally broadcasted in conjunction with AMCP Nexus 2026.
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide and is a leading cause of progressive kidney dysfunction and end-stage kidney disease. Prior to updated recommendations in the 2025 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, IgAN management centered on proteinuria as the primary marker of disease control. However, new data now demonstrate that several targeted therapies can also slow the rate of estimated glomerular filtration decline, a critical surrogate for long-term kidney outcomes. With multiple recently approved and late-stage investigational agents targeting distinct points in IgAN pathophysiology, managed care professionals and pharmacists must critically evaluate this expanding evidence base and translate it into sound formulary, coverage, and utilization management decisions. This session will highlight how managed care professionals and pharmacists can leverage updated KDIGO recommendations and emerging clinical trial evidence to inform real-world coverage policy, formulary evaluation, and patient access strategies. The clinical and economic burden of IgAN will also be discussed, with a focus on approaches for managed care to support evidence-based decision-making that improves long-term outcomes and helps preserve kidney function for patients with IgAN.
Target audience: Managed Care Pharmacist
Type of activity: Application
Release date: November 13, 2026
Expiration date: November 13, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the pathophysiology, disease burden, and predictors of progression in immunoglobulin A nephropathy (IgAN) and implications for patient management
- Apply updated KDIGO guidance and emerging clinical evidence to treatment decision-making for patients with IgAN
- Compare currently available and late-stage investigational therapies for IgAN, including evaluating efficacy, safety, molecular targets, and potential impact on disease progression
- Examine managed care approaches to formulary evaluation, coverage policy development, and patient access that support optimal outcomes for individuals living with IgAN
Branden D. Nemecek, PharmD, BCPS, FCCP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Internal Medicine and Nephrology Clinical Pharmacist
UPMC Mercy Hospital
Pittsburgh, PA
Ami Gopalan, PharmD, MBA, FAMCP
Senior Vice President, Strategic Content and Growth Optimization
Precision AQ
Chicago, IL
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-9999-26-353-H01-P. The activity is available for CE credit through November 13, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Ami Gopalan, PharmD, MBA, FAMCP, has the following relevant financial relationships with ineligible companies to disclose:
Other Support: Otsuka; Employee: Precision AQ
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Branden D. Nemecek, PharmD, BCPS, FCCP
The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
AI Disclosure
Artificial intelligence (AI) tools may have been used to support the development of this continuing education activity, such as for data organization or slide design. All AI-assisted content was reviewed and verified by qualified staff, faculty, or planners before release to ensure accuracy, balance, and freedom from commercial bias. Where applicable, specific details regarding the AI tool, its purpose, and the review process are disclosed within the activity materials. The accredited provider retains full responsibility for the activity's content, accuracy, balance, and independence.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms